**Core Concept**
Bevacizumab is a recombinant humanized monoclonal antibody that targets vascular endothelial growth factor (VEGF), a key mediator of angiogenesis. By binding to VEGF, bevacizumab inhibits the formation of new blood vessels, thereby suppressing tumor growth.

**Why the Correct Answer is Right**
Bevacizumab is used in the treatment of various cancers, including colorectal, breast, lung, and brain tumors. Its mechanism of action involves the inhibition of VEGF, which is a potent angiogenic factor that promotes the growth of new blood vessels. By blocking VEGF, bevacizumab reduces tumor perfusion, leading to decreased tumor growth and metastasis. The drug is often used in combination with chemotherapy and radiation therapy to enhance treatment efficacy.

**Why Each Wrong Option is Incorrect**
**Option A:** Bevacizumab is not primarily used to treat hypertension. While it may have some indirect effects on blood pressure due to its anti-angiogenic properties, its primary indication is not for the management of hypertension.
**Option B:** Bevacizumab is not a hormone therapy agent. It is a monoclonal antibody that targets VEGF, not hormones such as estrogen or testosterone.
**Option C:** Bevacizumab is not a first-line treatment for asthma. Its anti-angiogenic properties may have some indirect effects on airway inflammation, but it is not a standard treatment for asthma.

**Clinical Pearl / High-Yield Fact**
Bevacizumab is associated with an increased risk of hypertension, proteinuria, and thromboembolic events due to its anti-angiogenic effects. Patients receiving bevacizumab should be closely monitored for these adverse effects.

**Correct Answer:** C.